Independent · evidence-anchored—Reviewed by the GLPHelper Medical Team
EN·ES·For Providers ↗
glp·helper
Find a Provider →
glphelper.com/wegovy/new-jersey
GLP-1 receptor agonistFDA-approved June 2021Rx · Subcutaneous injection · Once weekly

Wegovy® Providers &
Prescriptions in New Jersey

Verified Wegovy providers across New Jersey. Checked against the NPI registry, sorted by waitlist — not by who pays us.[7]

state providers
92
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25–$1,150
monthly
01 / Find
stateNEW JERSEY
Search 92 results →
Popular →
Filters: insurance, telehealth, waitlist, dose
§ 01Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults — same molecule as Ozempic, higher dose.

Wegovy is the brand name for semaglutide at the higher 2.4 mg dose — the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]

In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9% — roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]

At a glanceNDC 0169-4525
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
June 2021
Approved use
Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Off-label use
Off-label use is uncommon — Ozempic is the FDA-approved formulation for type 2 diabetes
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy
§ 02Clinical evidence
STEP 1–4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize results from the STEP program — the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication — and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.

STEP-1 randomized 1,961 adults with obesity to weekly 2.4 mg semaglutide vs placebo over 68 weeks. Mean body-weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of patients on semaglutide achieved ≥ 5% weight loss vs 31.5% on placebo.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
Weight change
−14.9%
vs −2.4% placebo, 68 wk[4]
≥ 5% weight loss
86.4%
vs 31.5% placebo[4]
≥ 15% weight loss
50.5%
vs 4.9% placebo[4]
Major adverse cardiac events
−20%
HR 0.80 vs. placebo (SELECT)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
§ 04Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%) — more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
44%
mild
More common than at Ozempic doses; usually transient and dose-dependent
Diarrhea
30%
mild
Most frequent during dose escalation phase
Vomiting
24%
mild
Slower titration reduces incidence
Constipation
24%
mild
Hydration + fiber recommended
Abdominal pain
20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; class warning
Gallbladder disease
1.6%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 05Cost & coverage — published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$1,300 – $1,500
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 – $400
per month copay
Varies by PBM; many plans require BMI ≥ 30 + step therapy
Commercial insurance (denied)
Typically denied
—
Most plans exclude weight-loss medications from formulary
Medicare Part D
Not covered
—
Statutory exclusion of weight-loss drugs in original Medicare[5]
Manufacturer savings card
as low as $0
per month for 12 mo
Commercial only; eligibility limits apply
Compounded semaglutide
$150 – $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
§ 06Provider directory — New Jersey
34 of 34 shown

Find an Wegovy provider in New Jersey.

Every entry is checked against the NPI registry and the New Jersey medical board. Listings are ordered by current waitlist — the provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
§ 07Frequently asked — Wegovy in New Jersey

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources — never marketing copy.

FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]